2nd Quarter - Report

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Firm
Client
Income
—
Expenses
$4,400,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Korea Free Trade Agreement: Implementation issues related to intellectual property, market access and public health Colombia Free Trade Agreement: Implementation issues related to intellectual property, market access and public health Trans-Pacific Partnership (TPP): Provisions related to intellectual property, market access and public health issues Mexico and Canada IP and market access issuesTurkey Market Access Issues India innovation, IP and market access issues Transatlantic Trade and Investment Partnership (TTIP): Market access, intellectual property, regulatory and other issues The Agriculture Reform, Food and Jobs Act of 2013/H.R. 1947, Federal Agriculture Reform and Risk Management Act of 2013: Issues related to World Trade Organization (WTO) Brazil Cotton dispute Issues related to Special 301 and National Trade Estimate (NTE) submissions including intellectual property and market access issues International market access and intellectual property issues Biopharmaceutical innovation policy issues

Contacted: Federal Trade Commission (FTC); Executive Office of the President (EOP); SENATE; U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); White House Office; Health & Human Services, Dept of (HHS); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; Natl Security Council (NSC); Food & Drug Administration (FDA); Commerce, Dept of (DOC)

Bills named: H.R. 1947 (113th)

Health Issues HCR

H.R. 1263, Excellence in Mental Health Act: Sets forth criteria for the certification of federally-qualified community behavioral health centers H.R. 2674, 340B Program Improvement Act: Provisions related to 340B (112th Congress) H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013: Provisions related to supply chain securityH.R. 2090, Patient Choice Act of 2013: To permit provisional approval of fast track products H.R. 2415, Treat and Reduce Obesity Act of 2013: To include coverage of obesity drugs in Part D H.R. 6584, Verifying Authority and Legality In Drug Compounding Act: Provisions relating to drug compounding (112th Congress) S. 264, Excellence in Mental Health Act: Sets forth criteria for the certification of federally-qualified community behavioral health centers S. 1699, Prescription Drug Cost Reduction Act: Provisions related to 340B (112th Congress) S. 3187, Food and Drug Administration Safety and Innovation Act: Provisions related to user fee reauthorization and FDA reform (112th Congress) S. 957, Drug Supply Chain Security Act: Provisions related to supply chain security S. 959, Pharmaceutical Compounding Quality and Accountability Act: Provisions related to pharmaceutical compounding S. 2295, Patient Safety and Generic Labeling Improvement Act: Provisions related to drug safety labeling (112th Congress) Implementation issues relating to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including PPACA; Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking Comparative effectiveness policy issues Academic detailing policy issues General HHS and FDA related advocacy Biopharmaceutical innovation policy issues Pharmaceutical supply chain security issues Pharmaceutical compounding policy issues Prescription drug abuse policy issues FDA accelerated approval policy issues Unapproved use policy issues 340B policy issues

Contacted: Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; White House Office; Food & Drug Administration (FDA); State, Dept of (DOS); U.S. Trade Representative (USTR); Federal Trade Commission (FTC); SENATE; Executive Office of the President (EOP); Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); Natl Security Council (NSC)

Bills named: H.R. 1919 (113th), S. 264 (113th), H.R. 2674 (113th), H.R. 6584 (113th), H.R. 1263 (113th), S. 1699 (113th), S. 957 (113th), S. 959 (113th), H.R. 2415 (113th), S. 2295 (113th), S. 3187 (113th)

Medicare/Medicaid MMM

H.R. 8, American Taxpayer Relief Act of 2012: Medicare and tax related provisions (112th Congress) H.R. 351, Protecting Seniors' Access to Medicare Act of 2013: Provisions related to Independent Payment Advisory Board H.R. 928, Medicare Prescription Drug Savings and Choice Act of 2013: Provisions related to Part D issues H.R. 1588, Medicare Drug Savings Act of 2013: Provisions related to Part D issuesH.R. 460, Patients Access to Treatments Act of 2013: Provisions related to capping specialty tier drugs and no cost-sharing above the non-preferred brand tier S. 117, Medicare Prescription Drug Price Negotiation Act of 2013: Provisions related to Part D issues S. 351, Protecting Seniors Access to Medicare Act of 2013: Provisions related to Independent Payment Advisory Board S. 408, Medicare Prescription Drug Savings and Choice Act of 2013: Provisions related to Part D issues S. 740, Medicare Drug Savings Act of 2013: Provisions related to Part D issues Deficit reduction policy issues Medicaid Program, Covered Outpatient Drugs rulemaking Dual eligibles coordination policy issues Implementation issues relating to the Physician Payment Sunshine Act, including Medicare, Medicaid, Childrens Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests rulemaking

Contacted: Natl Security Council (NSC); White House Office; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Federal Trade Commission (FTC); Commerce, Dept of (DOC); SENATE; Patent & Trademark Office (PTO); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: S. 740 (113th), H.R. 928 (113th), S. 117 (113th), H.R. 351 (113th), S. 408 (113th), H.R. 8 (113th), H.R. 1588 (113th), S. 351 (113th)

Budget/Appropriations BUD

H.R. 2410, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2014: Provisions related to FDA regulation and funding, sequestration, drug importation H.R. 2217, Department of Homeland Security Appropriations Act, 2014: Provisions related to Customs and Border Control Agency funding, drug importsH.R. 2216, Military Construction and Veterans Affairs, and Related Agencies Appropriations Act, 2014: Provisions related to Veterans Affairs Administration regulation and funding, VA health benefits Department of Defense Appropriations Act, 2014 [no bill number]: Provisions related to bio-defense

Contacted: Natl Security Council (NSC); State, Dept of (DOS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; White House Office; Patent & Trademark Office (PTO); Federal Trade Commission (FTC); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Executive Office of the President (EOP)

Bills named: H.R. 2410 (113th), H.R. 2217 (113th)

Copyright/Patent/Trademark CPT

H.R. 22, Foreign Counterfeit Merchandise Prevention Act: Provisions related to counterfeiting H.R. 845, Saving High-Tech Innovators from Egregious Legal Disputes Act of 2013 (the SHIELD Act): Provisions related to patent litigation H.R. 2024, End Anonymous Patents Act: Patent owner information provisionsH.R. 2582, PATENT Jobs Act: Provisions related to patent user fees H.R. 2605, Manufacturing Innovation in America Act of 2013: Provisions related to patent tax boxes S. 214, Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 504, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 626, Prize Fund for HIV/AIDS Act: Medical prize provisions S. 627, Medical Innovation Prize Fund Act: Medical prize provisions S. 712, Patents for Humanity Program Improvement Act of 2013: Transferability of PTO vouchers provisions S. 866, Patent Quality Improvement Act of 2013: Business methods patents provisions S. 1013, Patent Abuse Reduction Act of 2013: Patent litigation provisions Biopharmaceutical innovation policy issues Potential legislation regarding patent litigation issues America Invents Act issues including estoppel for post grant review Biologics data protection issues Counterfeit drug issues Premerger Notification; Reporting and Waiting Period Requirements; Notice of proposed rulemaking (77 Federal Register 50057)

Contacted: State, Dept of (DOS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); SENATE; White House Office; Federal Trade Commission (FTC); Natl Security Council (NSC); U.S. Trade Representative (USTR); Executive Office of the President (EOP)

Bills named: S. 626 (113th), S. 504 (113th), H.R. 2605 (113th), S. 712 (113th), S. 1013 (113th), S. 627 (113th), H.R. 22 (113th), H.R. 845 (113th), H.R. 2024 (113th), S. 214 (113th), S. 866 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.